In Vivo Glycan Engineering via the Mannosidase I Inhibitor (Kifunensine) Improves Efficacy of Rituximab Manufactured in


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
07 Jan 2019
Historique:
received: 15 11 2018
revised: 20 12 2018
accepted: 02 01 2019
entrez: 10 1 2019
pubmed: 10 1 2019
medline: 2 5 2019
Statut: epublish

Résumé

N-glycosylation has been shown to affect the pharmacokinetic properties of several classes of biologics, including monoclonal antibodies, blood factors, and lysosomal enzymes. In the last two decades, N-glycan engineering has been employed to achieve a N-glycosylation profile that is either more consistent or aligned with a specific improved activity (i.e., effector function or serum half-life). In particular, attention has focused on engineering processes in vivo or in vitro to alter the structure of the N-glycosylation of the Fc region of anti-cancer monoclonal antibodies in order to increase antibody-dependent cell-mediated cytotoxicity (ADCC). Here, we applied the mannosidase I inhibitor kifunensine to the

Identifiants

pubmed: 30621113
pii: ijms20010194
doi: 10.3390/ijms20010194
pmc: PMC6337617
pii:
doi:

Substances chimiques

Alkaloids 0
Antigens, CD20 0
Polysaccharides 0
kifunensine 0NI8960271
Fucose 28RYY2IV3F
Rituximab 4F4X42SYQ6
Mannosidases EC 3.2.1.-
mannosyl-oligosaccharide 1,2-alpha-mannosidase EC 3.2.1.113
Mannose PHA4727WTP

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Nat Biotechnol. 1999 Feb;17(2):176-80
pubmed: 10052355
Science. 1999 Dec 3;286(5446):1882-8
pubmed: 10583943
J Biol Chem. 2001 Apr 20;276(16):12885-92
pubmed: 11278527
Biotechnol Bioeng. 2001 Aug 20;74(4):288-94
pubmed: 11410853
J Biol Chem. 2002 Jul 26;277(30):26733-40
pubmed: 11986321
J Biol Chem. 2003 Jan 31;278(5):3466-73
pubmed: 12427744
FEBS Lett. 2004 Mar 12;561(1-3):132-6
pubmed: 15013764
Cancer Res. 2004 Mar 15;64(6):2127-33
pubmed: 15026353
Biotechnol Bioeng. 2004 Sep 5;87(5):614-22
pubmed: 15352059
Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6248-55
pubmed: 15448014
Biotechnol Bioeng. 2004 Dec 30;88(7):901-8
pubmed: 15515168
Biotechnol Bioeng. 2006 Apr 5;93(5):851-61
pubmed: 16435400
Glycobiology. 2007 Jan;17(1):104-18
pubmed: 17012310
Nat Biotechnol. 2006 Dec;24(12):1591-7
pubmed: 17128273
Plant Biotechnol J. 2004 Nov;2(6):517-23
pubmed: 17147624
Structure. 2007 Mar;15(3):267-73
pubmed: 17355862
Biotechnol Bioeng. 2008 Feb 15;99(3):652-65
pubmed: 17680659
Biologicals. 2008 Jan;36(1):41-7
pubmed: 17890101
BMC Biotechnol. 2007 Nov 30;7:84
pubmed: 18047682
Plant Biotechnol J. 2008 May;6(4):392-402
pubmed: 18346095
Plant Biotechnol J. 2008 Sep;6(7):702-21
pubmed: 18498310
Glycobiology. 2010 Jan;20(1):24-32
pubmed: 19741058
Glycobiology. 2011 Jul;21(7):949-59
pubmed: 21421994
J Biol Chem. 1990 Sep 15;265(26):15599-605
pubmed: 2144287
J Biol Chem. 2011 Dec 16;286(50):43454-64
pubmed: 22006919
MAbs. 2012 Jul-Aug;4(4):509-20
pubmed: 22669558
MAbs. 2012 Jul-Aug;4(4):475-87
pubmed: 22699308
J Am Chem Soc. 2012 Jul 25;134(29):12308-18
pubmed: 22747414
Nat Immunol. 2014 Aug;15(8):707-16
pubmed: 25045879
Front Immunol. 2014 Oct 20;5:520
pubmed: 25368619
Immunotherapy. 2014;6(11):1187-206
pubmed: 25496334
MAbs. 2015;7(1):9-14
pubmed: 25529996
Ann Med Surg (Lond). 2014 Sep 11;3(4):113-6
pubmed: 25568796
Sci Rep. 2015 Jan 23;5:8003
pubmed: 25614217
Plant Biotechnol J. 2016 Feb;14(2):533-42
pubmed: 26011187
Biotechnol Prog. 2015 Sep-Oct;31(5):1433-41
pubmed: 26179435
Glycobiology. 2015 Dec;25(12):1325-34
pubmed: 26263923
Mol Immunol. 1989 Dec;26(12):1113-23
pubmed: 2633046
Plant Biotechnol J. 2015 Oct;13(8):1180-90
pubmed: 26387511
Glycobiology. 2016 Sep;26(9):926-939
pubmed: 26911286
MAbs. 2016 Nov/Dec;8(8):1456-1466
pubmed: 27559626
Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):3485-3490
pubmed: 28289219
J Pharm Biomed Anal. 2017 Jun 5;140:239-251
pubmed: 28371718
Trends Immunol. 2017 May;38(5):358-372
pubmed: 28385520
BioDrugs. 2017 Jun;31(3):151-166
pubmed: 28466278
Int J Mol Sci. 2018 Jan 31;19(2):null
pubmed: 29385073
Front Plant Sci. 2018 Jan 30;9:62
pubmed: 29441088
Int J Mol Sci. 2018 Mar 17;19(3):null
pubmed: 29562594
Sci Rep. 2018 Oct 31;8(1):16130
pubmed: 30382146
J Cell Sci Suppl. 1988;9:121-33
pubmed: 3077136
J Biol Chem. 1983 Mar 25;258(6):4032-6
pubmed: 6403522
J Biol Chem. 1995 Jan 6;270(1):369-75
pubmed: 7529232
Nat Med. 1995 Mar;1(3):237-43
pubmed: 7585040
J Biol Chem. 1994 Mar 18;269(11):8362-5
pubmed: 8132559
Mol Immunol. 1995 Dec;32(17-18):1311-8
pubmed: 8643100
Plant J. 1997 Feb;11(2):313-25
pubmed: 9076996
J Clin Oncol. 1997 Oct;15(10):3266-74
pubmed: 9336364

Auteurs

Vally Kommineni (V)

iBio CDMO, LLC, 8800 Health Science Center Parkway, Bryan, TX 77807, USA. vkommineni@ibiocmo.com.

Matthew Markert (M)

iBio CDMO, LLC, 8800 Health Science Center Parkway, Bryan, TX 77807, USA. mmarkert@ibiocmo.com.

Zhongjie Ren (Z)

iBio CDMO, LLC, 8800 Health Science Center Parkway, Bryan, TX 77807, USA. zren@ibiocmo.com.

Sreenath Palle (S)

iBio CDMO, LLC, 8800 Health Science Center Parkway, Bryan, TX 77807, USA. spalle@ibiocmo.com.

Berenice Carrillo (B)

iBio CDMO, LLC, 8800 Health Science Center Parkway, Bryan, TX 77807, USA. bcarrillo@ibiocmo.com.

Jasmine Deng (J)

iBio CDMO, LLC, 8800 Health Science Center Parkway, Bryan, TX 77807, USA. jdeng@ibiocmo.com.

Armando Tejeda (A)

iBio CDMO, LLC, 8800 Health Science Center Parkway, Bryan, TX 77807, USA. atejeda@ibiocmo.com.

Somen Nandi (S)

Global HealthShare® Initiative, University of California at Davis, Davis, CA 95616, USA. snandi@ucdavis.edu.
Department of Chemical Engineering, University of California at Davis, Davis, CA 95616, USA. snandi@ucdavis.edu.

Karen A McDonald (KA)

Global HealthShare® Initiative, University of California at Davis, Davis, CA 95616, USA. kamcdonald@ucdavis.edu.
Department of Chemical Engineering, University of California at Davis, Davis, CA 95616, USA. kamcdonald@ucdavis.edu.

Sylvain Marcel (S)

iBio CDMO, LLC, 8800 Health Science Center Parkway, Bryan, TX 77807, USA. smarcel@ibiocmo.com.

Barry Holtz (B)

iBio CDMO, LLC, 8800 Health Science Center Parkway, Bryan, TX 77807, USA. bholtz@ibioinc.com.

Articles similaires

Animals Flax Chickens Dietary Supplements Endo-1,4-beta Xylanases
Saccharomyces cerevisiae Aldehydes Biotransformation Flavoring Agents Lipoxygenase
Protein Processing, Post-Translational Humans Blood Coagulation Fibrin Fibrinogen

Metabolic engineering of

Jae Sung Cho, Zi Wei Luo, Cheon Woo Moon et al.
1.00
Corynebacterium glutamicum Metabolic Engineering Dicarboxylic Acids Pyridines Pyrones

Classifications MeSH